Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure
Authors: Ayers Emily C. , Li Shaoying , Medeiros L. Jeffrey , Bond David A. , Maddocks Kami J. , Torka Pallawi , Mier Hicks Angel , Curry Madeira , Wagner‐Johnston Nina D. , Karmali Reem , Behdad Amir , Fakhri Bita , Kahl Brad S. , Churnetski Michael C. , Cohen Jonathon B. , Reddy Nishitha M. , Modi Dipenkumar , Ramchandren Radhakrishnan , Howlett Christina , Leslie Lori A. , Cytryn Samuel , Diefenbach Catherine S. , Faramand Rawan , Chavez Julio C. , Olszewski Adam J. , Liu Yang , Barta Stefan K. , Mukhija Dhruvika , Hill Brian T. , Ma Helen , Amengual Jennifer E. , Nathan Sunita , Assouline Sarit E. , Orellana‐Noia Victor M. , Portell Craig A. , Chandar Ashwin , David Kevin A. , Giri Anshu , Hess Brian T. , Landsburg Daniel J. 
Published: October 2019

BackgroundSalvage immunochemotherapy followed by high‐dose chemotherapy and autologous stem cell transplantation is the standard‐of‐care second‐line treatment for patients with relapsed/refractory diffuse large B‐cell lymphoma after first‐line R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Outcomes after receipt of second‐line immunochemotherapy in patients with aggressive B‐cell lymphomas who relapse or are refractory to intensive first‐line immunochemotherapy regimens (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab [R‐EPOCH], rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytarabine [R‐HyperCVAD], rituximab, cyclophosphamide, vincristine, doxorubicin, and high‐dose methotrexate alternating with ifosfamide, etoposide, and cytarabine [R‐CODOX‐M/IVAC]) remain unknown.MethodsOutcomes of patients with non‐Burkitt, aggressive B‐cell lymphomas and relapsed/refractory disease after first‐line treatment with intensive immunochemotherapy regimens who received platinum‐based second‐line immunochemotherapy were reviewed retrospectively. Analyses were performed to determine progression‐free survival (PFS) and overall survival (OS) from the time of receipt of second‐line immunochemotherapy.ResultsIn total, 195 patients from 19 academic centers were included in the study. The overall response rate to second‐line immunochemotherapy was 44%, with a median PFS of 3 months and a median OS of 8 months. Patients with early treatment failure (primary refractory or relapse <12 months from completion of first‐line therapy) experienced inferior median PFS (2.8 vs 23 months; P < .001) and OS (6 months vs not reached; P < .001) compared with patients with late treatment failure. Although the 17% of patients with early failure who achieved a complete response to second‐line immunochemotherapy experienced prolonged survival, this outcome could not be predicted by clinicopathologic features at the start of second‐line immunochemotherapy.ConclusionsPatients with early treatment failure after intensive first‐line immunochemotherapy experience poor outcomes after receiving standard second‐line immunochemotherapy. The use of standard‐of‐care or experimental therapies currently available in the third‐line setting and beyond should be investigated in the second‐line setting for these patients.